164 related articles for article (PubMed ID: 26807262)
41. Case Report: A Novel Compound Heterozygote Mutation of the
Liu Z; Wang X; Zhang Z; Yang Z; Wang J; Wang Y
Front Pediatr; 2022; 10():831284. PubMed ID: 35359893
[TBL] [Abstract][Full Text] [Related]
42. [Electrolyte abnormalities and metabolic acidosis in two Duchenne muscular dystrophy patients with advanced congestive heart failure].
Matsumura T; Saito T; Miyai I; Nozaki S; Kang J
Rinsho Shinkeigaku; 2000 May; 40(5):439-45. PubMed ID: 11002725
[TBL] [Abstract][Full Text] [Related]
43. Miliaria rubra and thrombocytosis in pseudohypoaldosteronism: case report.
Onal H; Adal E; Ersen A; Onal Z; Keskindemirci G
Platelets; 2012; 23(8):645-7. PubMed ID: 22150373
[TBL] [Abstract][Full Text] [Related]
44. 30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor mutations.
Zennaro MC; Fernandes-Rosa F
J Endocrinol; 2017 Jul; 234(1):T93-T106. PubMed ID: 28348114
[TBL] [Abstract][Full Text] [Related]
45. Localisation of pseudohypoaldosteronism genes to chromosome 16p12.2-13.11 and 12p13.1-pter by homozygosity mapping.
Strautnieks SS; Thompson RJ; Hanukoglu A; Dillon MJ; Hanukoglu I; Kuhnle U; Seckl J; Gardiner RM; Chung E
Hum Mol Genet; 1996 Feb; 5(2):293-9. PubMed ID: 8824886
[TBL] [Abstract][Full Text] [Related]
46. A novel nonsense mutation of the mineralocorticoid receptor gene in a Swedish family with pseudohypoaldosteronism type I (PHA1).
Nyström AM; Bondeson ML; Skanke N; Mårtensson J; Strömberg B; Gustafsson J; Annerén G
J Clin Endocrinol Metab; 2004 Jan; 89(1):227-31. PubMed ID: 14715854
[TBL] [Abstract][Full Text] [Related]
47. Mineralocorticoid receptor mutations are the principal cause of renal type 1 pseudohypoaldosteronism.
Pujo L; Fagart J; Gary F; Papadimitriou DT; Claës A; Jeunemaître X; Zennaro MC
Hum Mutat; 2007 Jan; 28(1):33-40. PubMed ID: 16972228
[TBL] [Abstract][Full Text] [Related]
48. Mineralocorticoid resistance.
Zennaro MC; Lombès M
Trends Endocrinol Metab; 2004 Aug; 15(6):264-70. PubMed ID: 15358279
[TBL] [Abstract][Full Text] [Related]
49. Severe hyperkalemia is rescued by low-potassium diet in renal βENaC-deficient mice.
Boscardin E; Perrier R; Sergi C; Maillard M; Loffing J; Loffing-Cueni D; Koesters R; Rossier BC; Hummler E
Pflugers Arch; 2017 Oct; 469(10):1387-1399. PubMed ID: 28567665
[TBL] [Abstract][Full Text] [Related]
50. Restoration of Epithelial Sodium Channel Function by Synthetic Peptides in Pseudohypoaldosteronism Type 1B Mutants.
Willam A; Aufy M; Tzotzos S; Evanzin H; Chytracek S; Geppert S; Fischer B; Fischer H; Pietschmann H; Czikora I; Lucas R; Lemmens-Gruber R; Shabbir W
Front Pharmacol; 2017; 8():85. PubMed ID: 28286482
[TBL] [Abstract][Full Text] [Related]
51. The ENaC channel as the primary determinant of two human diseases: Liddle syndrome and pseudohypoaldosteronism.
Schild L
Nephrologie; 1996; 17(7):395-400. PubMed ID: 8987044
[TBL] [Abstract][Full Text] [Related]
52. Suppression of plasma renin activity in a boy with chronic hyperkalemia.
Sauder SE; Kelch RP; Grekin RJ; Kelsch RC
Am J Dis Child; 1987 Aug; 141(8):922-7. PubMed ID: 3307388
[TBL] [Abstract][Full Text] [Related]
53. Evidence for genetic heterogeneity of pseudohypoaldosteronism type 1: identification of a novel mutation in the human mineralocorticoid receptor in one sporadic case and no mutations in two autosomal dominant kindreds.
Viemann M; Peter M; López-Siguero JP; Simic-Schleicher G; Sippell WG
J Clin Endocrinol Metab; 2001 May; 86(5):2056-9. PubMed ID: 11344206
[TBL] [Abstract][Full Text] [Related]
54. Pseudohypoaldosteronism in a neonate presenting as life-threatening arrhythmia.
Rajpoot SK; Maggi C; Bhangoo A
Endocrinol Diabetes Metab Case Rep; 2014; 2014():130077. PubMed ID: 24688761
[TBL] [Abstract][Full Text] [Related]
55. Adult nephron-specific MR-deficient mice develop a severe renal PHA-1 phenotype.
Canonica J; Sergi C; Maillard M; Klusonova P; Odermatt A; Koesters R; Loffing-Cueni D; Loffing J; Rossier B; Frateschi S; Hummler E
Pflugers Arch; 2016 May; 468(5):895-908. PubMed ID: 26762397
[TBL] [Abstract][Full Text] [Related]
56. Clinical features and molecular basis of pseudohypoaldosteronism type 1.
Tajima T; Morikawa S; Nakamura A
Clin Pediatr Endocrinol; 2017; 26(3):109-117. PubMed ID: 28804203
[TBL] [Abstract][Full Text] [Related]
57. Autosomal Dominant Pseudohypoaldosteronism Type 1 in a Newborn With Failure to Thrive.
Krishna S; Augustian M
Cureus; 2024 Apr; 16(4):e59356. PubMed ID: 38689677
[TBL] [Abstract][Full Text] [Related]
58. A novel frameshift mutation in NR3C2 leads to decreased expression of mineralocorticoid receptor: a family with renal pseudohypoaldosteronism type 1.
Kawashima Sonoyama Y; Tajima T; Fujimoto M; Hasegawa A; Miyahara N; Nishimura R; Hashida Y; Hayashi A; Hanaki K; Kanzaki S
Endocr J; 2017 Jan; 64(1):83-90. PubMed ID: 27725360
[TBL] [Abstract][Full Text] [Related]
59. Pseudohypoaldosteronism type 1 due to a novel mutation in the mineralocorticoid receptor gene.
Loomba-Albrecht LA; Nagel M; Bremer AA
Horm Res Paediatr; 2010; 73(6):482-6. PubMed ID: 20453518
[TBL] [Abstract][Full Text] [Related]
60. Transient pseudo-hypoaldosteronism following resection of the ileum: normal level of lymphocytic aldosterone receptors outside the acute phase.
Vantyghem MC; Hober C; Evrard A; Ghulam A; Lescut D; Racadot A; Triboulet JP; Armanini D; Lefebvre J
J Endocrinol Invest; 1999 Feb; 22(2):122-7. PubMed ID: 10195379
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
